Turn Therapeutics’ eczema drug shows rapid response in mid-stage datanews2026-06-01T12:51:57+00:00June 1st, 2026|Endpoints News|
Servier signs $1.55B upfront deal for Edgewise’s muscular dystrophy assetsnews2026-06-01T12:31:49+00:00June 1st, 2026|Endpoints News|
#ASCO26: AstraZeneca’s triplet combo succeeds in liver cancer subgroupnews2026-06-01T12:00:27+00:00June 1st, 2026|Endpoints News|
Lilly licenses GLP-2 asset from Korean biotech Hanmi for $75M upfrontnews2026-06-01T10:43:21+00:00June 1st, 2026|Endpoints News|
#ASCO26: Erleada succeeds in early-stage prostate cancer study, but questions remainnews2026-06-01T10:19:50+00:00June 1st, 2026|Endpoints News|
Australia sues 3M over firefighting foam PFAS contaminationnews2026-06-01T08:56:00+00:00June 1st, 2026|Chemistry World|
